. Author manuscript; available in PMC: 2021 Jul 9.

Published in final edited form as: Cancer Res. 2020 Jun 12;80(16):3399–3412. doi: 10.1158/0008-5472.CAN-19-3599

Table 1. Overview of the functional characteristics of the improved constructs.

	Biological activity characteristics
mAb	avidity^b Kd (nmol/L)	direct cytotoxicity^a EC₅₀ (nmol/L)	ADCC EC₅₀ (nmol/L)	CDC EC₅₀ (nmol/L)	Pore forming ability
88mIgG3	0.3	26.7	ND	ND	+++
88hIgG1	48.3	N/A	0.13	3.9	-
i88G1	0.5	29.4	0.35	0.1	++
129hIgG1	2.5	N/A	1.7	75.3	-
i129G1	0.005	45.6	2.4	8.2	++

deduced from proliferation inhibition on COLO205

N/A: not appropriate, ND: not determined

sensorgrams underlying the avidity determination are shown in Supplementary Fig. 3